CN103405388B - Wettable moxidectin solid dispersing powder as well as preparation method and application thereof - Google Patents
Wettable moxidectin solid dispersing powder as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN103405388B CN103405388B CN201310367102.2A CN201310367102A CN103405388B CN 103405388 B CN103405388 B CN 103405388B CN 201310367102 A CN201310367102 A CN 201310367102A CN 103405388 B CN103405388 B CN 103405388B
- Authority
- CN
- China
- Prior art keywords
- moxidectin
- parts
- wettability
- preparation
- solid dispersal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention provides wettable moxidectin solid dispersing powder. The wettable moxidectin solid dispersing powder is a medicinal preparation prepared from the following raw materials and auxiliary materials in weight proportion: 0.1-10 parts of moxidectin, 1.2-18 parts of hydroxypropyl-beta-cyclodextrin, 0.8-2.5 parts of poloxamer 188, 58.5-78.1 parts of anhydrous glucose, 11-20 parts of anhydrous sodium citrate and an antioxidant accounting for 0.02-0.05%w/w of the dosage of moxidectin, wherein the antioxidant is one or combination of more than two of hydroxyl methyl benzene butyl ester, butyl hydroxy anisole and propyl gallate. The invention also provides a preparation method and an application of the wettable moxidectin solid dispersing powder composition. The wettable moxidectin solid dispersing powder obtained by screening auxiliary materials can be used for guaranteeing the dispersibility of moxidectin, improving the treatment effect of a moxidectin preparation and also obviously improving the convenience of moxidectin in application, so that a new choice is provided for clinical medication.
Description
Technical field
The present invention relates to a kind of wettability moxidectin solid dispersal powder and its production and use.
Background technology
Moxidectin (Moxidectin, MXD) Chinese another name has Moxidectin, Moses Dinke, moxidectin, is streptomycete S.cyanneogrisens noncyanogenus tunning---the derivant of macrolide antibiotics how horse rhzomorph (Nemadectin).Different from the multicomponent such as ivermectin, avilamycin Macrolide antiparasitic, it is single component, belong to the 3rd generation Avermectins medicine milbemycin (Milbemycins) family, so have another name called milbemycin B(Milbemycin B); Molecular formula is C
37h
53nO
8; Molecular weight is 639.82, and molecular structure is:
MXD character is white or off-white color amorphous powder, water-soluble hardly, is very easily dissolved in ethanol, is slightly soluble in hexane; Compared with medicine similar with other, have higher fat-soluble, therefore MXD can combine with multiple excipient and make all kinds of preparation, have different administering modes and pharmacokinetics special.
MXD anthelmintic mechanism is identical with ivermectin.Compared with ivermectin, MXD has higher anthelmintic activity and the characteristic such as long-acting, safe, especially to nematicide (adult and larva) and arthropod, under extremely low dosage, just has good anti-insect activity.Have the nematicide of dog, cattle, sheep, horse and arthropod parasites and highly drive away activity.Due to fat-soluble higher compared with tool of MXD, therefore, the treatment active drug concentration maintaining tissue is more lasting.In cattle body, the metabolite of MXD is the methylolation product of C-29/30 and C-14 position, and minute quantity hydroxylating and O-demethylated product.MXD is mainly through defecate, and through homaluria is 3%.
The existing tablet of MXD, solution, injection and water and drench agent four kinds of dosage form product, be mainly used in the most of gastrointestinal nematode and the thread lungworm that ruminate beast and horse, ruminate some arthropod parasites of beast, and the larva that heart worm grows.
Cattle mainly uses MXD injection and dashing agent.MXD is to the adult of 10 kinds of nematicides such as Ostertagia orloffi and larva effective percentage >99%; To saddle anus nematodirus effective percentage >95%; Be 92% ~ 100% to the adult of 4 kinds of nematicides such as cooperia oncophora and larva effective percentage.After once applying, prevention repeated infection reaches the polypide of 28 days for phase spy nematicide difficult to understand, haemonchus and Oesophagostomum.To thread lungworm even more than 28 days; Also 7 days can be reached to nematodirus and the above-mentioned effect of cooperid.One time subcutaneous injection MXD can get rid of acaricide and itch mite completely, though a local application is effective to itch mite.Subcutaneous injection makes boophilus microplus reduce 95%, keeps the depression effect to polypide in 32 days in medication always; Have data to show, injection and dashing agent to sucking property epizoa, as haematopinus eurysternus, cattle palate louse, cattle pipe louse and cattle grain leather fly larvae effective percentage reach 99% ~ 100%.The effect of dashing agent to ox hair louse is more better than injection.
MXD to sheep for oral administration to haemonchus, ostertagi, trichostrongyle, cooperid, Oesophagostomum, Xia Baite nematicide and net filaria adult and larva and nematodirus effective percentage more than 99%.In addition, fabulous curative effect is also had to sheep itch mite.In New Zealand, also permit the deer group of dashing agent for raising, and practice result shows MXD to haemonchus, ostertagi, trichostrongyle, esophageal orifice line, net filaria expeling rate more than 99%.
MXD is applied to horse by 400 μ g/kg dosage, very effective to common entozoa.Measure to horse MXD gelatin formulation by 300 μ g/kg, to the soft nematicide of fly, parascaris equorum, oxyuris equi adult and larva and typical circular nematicide, anodontia strongyle and Triodontophorus nematicide and adult effective percentage more than 99%.To cup mouth nematode adult and First Line phase larva expeling rate more than 97%.
The anthelmintic action of MXD to dog is similar with milbemycin, namely have efficiently to ancylostoma caninum, but ancylostome and European ancylostoma caninum poor effect are belonged to curved mouth, because the former once 25 μ g/kg amounts for oral administration namely have good effect to ancylostoma caninum, and to a rear worm kind need with 150 μ g/kg measure the beginnings reach equivalent should; The preventive effect of low dosage MXD to heart worm is similar to ivermectin, as by 3 μ g/kg dosage to heart worm one monthly age and February instar larvae expeling rate reach 100%.MXD is safer to animal, and the shepherd dog that becomes mildewed (Collies) the also safety to ivermectin sensitivity, but during high dose, the symptoms such as somnolence, vomiting, ataxia, anorexia, dysentery may appear in indivedual dog.
As anthelmintic drug of new generation, MXD can kill nematicide and ectozoa efficiently, meanwhile, has good safety to animal.It is better than ivermectin in dosage, formulation development, drug resistance and drug disposition distribution etc., because of but a kind of antiparasitic be worthy to be popularized, be necessary exploitation more utilization rates higher, use novel form more easily.
Summary of the invention
Technical scheme of the present invention there is provided a kind of wettability moxidectin solid dispersal powder.Another technical scheme of the present invention there is provided the preparation method of this wettability moxidectin solid dispersal powder.
The invention provides a kind of wettability moxidectin solid dispersal powder, it is the pharmaceutical preparation be prepared from by the supplementary material of following weight proportioning:
Moxidectin 0.1 ~ 10 part, HP-β-CD 1.2 ~ 18 parts, PLURONICS F87 0.8 ~ 2.5 part, anhydrous glucose 58.5 ~ 78.1 parts, 11 ~ 20 parts, anhydrous citric acid sodium; Antioxidant consumption is 0.02 ~ 0.05%w/w of moxidectin;
Antioxidant is selected from the one or more kinds of combinations in hydroxy toluene butyl ester, Butylated hydroxyanisole, propyl gallate.
Further, it is the pharmaceutical preparation be prepared from by the supplementary material of following weight proportioning:
Moxidectin 0.68 ~ 4.6 part, HP-β-CD 5.1 ~ 16 parts, PLURONICS F87 1.36 ~ 2.3 parts, anhydrous glucose 65.1 ~ 76.86 parts, 12 ~ 16 parts, anhydrous citric acid sodium; Antioxidant consumption is the 0.02%w/w of moxidectin.
Further, it is the pharmaceutical preparation be prepared from by the supplementary material of following weight proportioning:
Moxidectin 0.68 ~ 1.8 part, HP-β-CD 5.1 ~ 9.6 parts, PLURONICS F87 1.36 ~ 1.8 parts, anhydrous glucose 73.2 ~ 76.86 parts, 14 ~ 16 parts, anhydrous citric acid sodium; Oxidation preventive content is the 0.02%w/w of moxidectin.
Preferably, it is the pharmaceutical preparation be prepared from by the supplementary material of following weight proportioning:
Moxidectin 0.68 part, HP-β-CD 5.1 parts, PLURONICS F87 1.36 parts, anhydrous glucose 76.86 parts, 16 parts, anhydrous citric acid sodium, hydroxy toluene butyl ester content is the 0.02%w/w of moxidectin;
Or moxidectin 1.8 parts, HP-β-CD 9.6 parts, PLURONICS F87 1.8 parts, anhydrous glucose 73.2 parts, 14 parts, anhydrous citric acid sodium, hydroxy toluene butyl ester content is the 0.02%w/w of moxidectin.
Present invention also offers the preparation method of above-mentioned wettability moxidectin solid dispersal powder, it is characterized in that: it comprises the steps:
A. supplementary material is taken by weight ratio;
B. get moxidectin, HP-β-CD, PLURONICS F87, add dehydrated alcohol and antioxidant, stirring and dissolving, then add anhydrous glucose and anhydrous citric acid sodium mix homogeneously, dry, pulverize, obtain wettability moxidectin solid dispersal powder.
Present invention also offers the purposes of above-mentioned wettability moxidectin solid dispersal powder in the veterinary drug of preparation anthelmintic.
The present invention screens the wettability moxidectin solid dispersal powder obtained by adjuvant, ensure that the dispersibility of moxidectin, improve the therapeutic effect of moxidectin preparation, also considerably improves the ease of use of moxidectin, for clinical application provides new selection.
Detailed description of the invention
The preparation of embodiment 1 wettability moxidectin of the present invention solid dispersal powder
Get moxidectin 0.01kg, HP-β-CD 0.2kg, PLURONICS F87 0.1kg, add dehydrated alcohol 200ml, Butylated hydroxyanisole 4mg, be stirred to dissolve, add anhydrous glucose 7.89kg, anhydrous citric acid sodium 1.8kg, mix homogeneously, 50 DEG C of oven dry of ventilating, pulverize, obtain the present invention 0.1% wettability moxidectin solid dispersal powder.
The preparation of embodiment 2 wettability moxidectin of the present invention solid dispersal powder
Get moxidectin 0.2kg, HP-β-CD 1.2kg, PLURONICS F87 0.2kg, add dehydrated alcohol 1000ml, hydroxy toluene butyl ester 40mg, be stirred to dissolve, add anhydrous glucose 15.6kg, anhydrous citric acid sodium 2.8kg, mix homogeneously, 50 DEG C of oven dry of ventilating, pulverize, obtain the present invention 1.0% wettability moxidectin solid dispersal powder.
The preparation of embodiment 3 wettability moxidectin of the present invention solid dispersal powder
Get moxidectin 2.0kg, HP-β-CD 4.0kg, PLURONICS F87 0.5kg, add dehydrated alcohol 2000ml, propyl gallate 200mg, be stirred to dissolve, add anhydrous glucose 11.1kg, anhydrous citric acid sodium 2.4kg, mix homogeneously, 50 DEG C of oven dry of ventilating, pulverize, obtain the present invention 10.0% wettability moxidectin solid dispersal powder.
The recipe determination of embodiment 4 wettability moxidectin of the present invention solid dispersal powder
(1) preparation of different formulations product
By specifying containing measuring moxidectin, hydroxy toluene butyl ester, HP-β-CD, PLURONICS F87 under formula item each in table 1, add appropriate dehydrated alcohol, add antioxidant hydroxy toluene butyl ester (0.02% of moxidectin content) again, be stirred to dissolve, add anhydrous glucose fine powder and anhydrous citric acid sodium fine powder by ormal weight under corresponding formula item, be mixed into moistening soft material, 50 DEG C of oven dry of ventilating, pulverize, prepare wettability moxidectin solid dispersal powder of the present invention.
The preferred version of table 1 wettability moxidectin of the present invention solid dispersal powder formula
(2) quality evaluation of different formulations product
Dispersion is evaluated: get each 1g of wettability moxidectin solid dispersal powder by the preparation of table 1 formula 1 ~ formula 7, drops in 1000ml water, observes or stir and observe its deployment conditions.Disperse slower and to be unevenly chosen as " poor "; Dispersion is comparatively slow, and have caking or granule in dispersive process, agitation as appropriate can be uniformly dispersed, and is chosen as " qualified "; Dispersion is fast, and gentle agitation can be uniformly dispersed, and is chosen as " good "; Dispersion is fast, need not stir and can be uniformly dispersed, be chosen as " excellent ".The results are shown in Table 2.
Sedimentation volume ratio measures: by " solution for oral administration, suspensoid for oral administration, Emulsion for oral administration " sedimentation volume ratio inspection technique requirement in " People's Republic of China's veterinary drug allusion quotation (version in 2010) " annex, sedimentation volume ratio mensuration is carried out to the wettability moxidectin solid dispersal powder prepared by formula 1 ~ formula 7, sample thief 0.25g puts in 50ml tool plug graduated cylinder, add water to 50ml, fill in close, firmly jolting 1min, writes down suspended matter and starts height H
0, leave standstill and within 3 hours, write down the final height H of suspended matter, be calculated as follows: sedimentation volume ratio=H/H
0, sedimentation volume ratio should be not less than 0.90.The results are shown in Table 2.
Table 2 wettability moxidectin of the present invention solid dispersal powder quality evaluation result
Listed 4 indexs of his-and-hers watches 1 are carried out comprehensive analysis and can be obtained: formula 1 ~ formula 6 is all qualified, be wherein optimum with formula 3, formula 4 again.
Beneficial effect of the present invention is illustrated below by way of test example.
Test example 1 oral wettability moxidectin solid dispersal powder is to the clinical tests of goat acariasis
Material: moxidectin solution (100ml: 0.1g, commercially available prod); Wettability moxidectin solid dispersal powder (0.1%, prepared by embodiment 1).
Case: (sick sheep performance is very itched, lose hair or feathers, pachyderma and becoming thin for sheep acarid case 48 example of sheep field, Jianyang, Chengdu natural occurrence; Collect the scurf of disease sheep injury moistening, be directly coated on microscope slide, can be observed the demodicid mite that lives), sick sheep about body weight 30kg.
Method: at random sick sheep is divided into matched group, test group and negative control group under identical rearing conditions; The commercially available moxidectin solution of matched group is watered by 1% concentration, drinks for sick sheep; Wettability moxidectin solid dispersal powder prepared by test group embodiment 1 converts drinking water by 1% concentration, drinks for sick sheep; Negative control group supplies drinking-water, not administration by daily.
Efficacy determination method: medication is after 10 days, and spiritual appetite recovers normal, and microscopy, without the parasite lived or worm's ovum, is judged to recovery from illness; Medication is after 10 days, and spiritual appetite takes a turn for the better, the parasite that microscopy is lived as seen on a small quantity, is judged to effectively; Medication is after 10 days, and symptom is not improved, and it is invalid to be judged to.
Experimental result: in table 3.
Table 3 oral wettability moxidectin solid dispersal powder is to the clinical tests result of sheep acariasis
As can be seen from the test results, oral wettability moxidectin solid dispersal powder of the present invention is all better than commercially available moxidectin solution to the therapeutic effect of sheep acariasis.
Test example 2 injects wettability moxidectin solid dispersal powder to the clinical tests of heart worm
Material: moxidectin injection (5ml: 50mg, commercially available prod); Wettability moxidectin solid dispersal powder (10.0%, prepared by embodiment 3).
Case: heart worm case 23 example (sick dog shows the clinical symptoms such as circulatory disturbance, dyspnea and anemia, through ELISA quick detection kit test positive) that Chengdu pet clinic accepts for medical treatment, sick dog about body weight 10kg.
Method: in the treatment of sick dog, is divided into matched group, test group and negative control group at random under identical rearing conditions; Matched group is by every 10kg body weight 0.1ml subcutaneous injection moxidectin injection; By every 10kg body weight 0.1ml intramuscular injection after wettability moxidectin solid dispersal powder prepared by test group embodiment 3 is watered by 10% concentration; Negative control group not administration.
Efficacy determination method: medication is after 10 days, and clinical symptom disappearance, detects through ELISA quick detection kit and transfer feminine gender to, be judged to recovery from illness; Medication is after 10 days, and clinical symptoms takes a turn for the better, and it is still positive for detecting through ELISA quick detection kit, is judged to effectively; Medication is after 10 days, and symptom is not improved or increases the weight of, and it is still positive for detecting through ELISA quick detection kit, and it is invalid to be judged to.
Experimental result: in table 4.
Table 4 injects wettability moxidectin solid dispersal powder to the clinical tests result of heartworm disease
As can be seen from above result of the test, inject wettability moxidectin solid dispersal powder of the present invention suitable with the therapeutic effect of commercially available moxidectin injection to heartworm disease; The convenience that wettability moxidectin solid dispersal powder of the present invention uses is better than commercially available moxidectin injection, greatly reduces the working strength of administration.Also find in test, it is less to inject the stimulation of wettability moxidectin solid dispersal powder of the present invention to sick dog.
In sum, the present invention screens the wettability moxidectin solid dispersal powder obtained by adjuvant, ensure that the dispersibility of moxidectin, improve the therapeutic effect of moxidectin preparation, also considerably improves the ease of use of moxidectin, for clinical application provides new selection.
Claims (4)
1. a wettability moxidectin solid dispersal powder, is characterized in that:
It is the pharmaceutical preparation be prepared from by the supplementary material of following weight proportioning:
Moxidectin 0.68 ~ 1.8 part, HP-β-CD 5.1 ~ 9.6 parts, PLURONICS F87 1.36 ~ 1.8 parts, anhydrous glucose 73.2 ~ 76.86 parts, 14 ~ 16 parts, anhydrous citric acid sodium; Oxidation preventive content is the 0.02%w/w of moxidectin; Antioxidant is selected from the one or more kinds of combinations in hydroxy toluene butyl ester, Butylated hydroxyanisole, propyl gallate;
The preparation method of described solid dispersal powder, it comprises the steps:
A. supplementary material is taken by weight ratio;
B. get moxidectin, HP-β-CD, PLURONICS F87, add dehydrated alcohol and antioxidant, stirring and dissolving, then add anhydrous glucose and anhydrous citric acid sodium mix homogeneously, dry, pulverize, obtain wettability moxidectin solid dispersal powder.
2. wettability moxidectin solid dispersal powder according to claim 1, is characterized in that: it is the pharmaceutical preparation be prepared from by the supplementary material of following weight proportioning:
Moxidectin 0.68 part, HP-β-CD 5.1 parts, PLURONICS F87 1.36 parts, anhydrous glucose 76.86 parts, 16 parts, anhydrous citric acid sodium, hydroxy toluene butyl ester content is the 0.02%w/w of moxidectin;
Or moxidectin 1.8 parts, HP-β-CD 9.6 parts, PLURONICS F87 1.8 parts, anhydrous glucose 73.2 parts, 14 parts, anhydrous citric acid sodium, hydroxy toluene butyl ester content is the 0.02%w/w of moxidectin.
3. a preparation method for wettability moxidectin solid dispersal powder described in claim 1 or 2, is characterized in that: it comprises the steps:
A. supplementary material is taken by weight ratio;
B. get moxidectin, HP-β-CD, PLURONICS F87, add dehydrated alcohol and antioxidant, stirring and dissolving, then add anhydrous glucose and anhydrous citric acid sodium mix homogeneously, dry, pulverize, obtain wettability moxidectin solid dispersal powder.
4. the purposes of wettability moxidectin solid dispersal powder described in claim 1 or 2 in the veterinary drug of preparation anthelmintic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310367102.2A CN103405388B (en) | 2013-08-21 | 2013-08-21 | Wettable moxidectin solid dispersing powder as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310367102.2A CN103405388B (en) | 2013-08-21 | 2013-08-21 | Wettable moxidectin solid dispersing powder as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103405388A CN103405388A (en) | 2013-11-27 |
| CN103405388B true CN103405388B (en) | 2015-04-08 |
Family
ID=49598464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310367102.2A Expired - Fee Related CN103405388B (en) | 2013-08-21 | 2013-08-21 | Wettable moxidectin solid dispersing powder as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405388B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523681B (en) * | 2014-12-17 | 2017-01-11 | 南京农业大学 | Parasite expelling sustained and controlled-release bolus and preparation method thereof |
| CN105663085B (en) * | 2016-03-11 | 2018-08-10 | 安徽农业大学 | A kind of Paeonol nano controlled-release preparation and preparation method thereof |
| CN106075462A (en) * | 2016-06-08 | 2016-11-09 | 芜湖福民生物药业有限公司 | Stable moxidectin preparation and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103054808A (en) * | 2012-12-27 | 2013-04-24 | 成都乾坤动物药业有限公司 | Tilmicosin dry suspension, method for preparing dry suspension and uses thereof |
| US20130143956A1 (en) * | 2011-12-02 | 2013-06-06 | Merial Limited | Long-acting injectable moxidectin formulations and novel moxidectin crystal forms |
-
2013
- 2013-08-21 CN CN201310367102.2A patent/CN103405388B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130143956A1 (en) * | 2011-12-02 | 2013-06-06 | Merial Limited | Long-acting injectable moxidectin formulations and novel moxidectin crystal forms |
| CN103054808A (en) * | 2012-12-27 | 2013-04-24 | 成都乾坤动物药业有限公司 | Tilmicosin dry suspension, method for preparing dry suspension and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103405388A (en) | 2013-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101686962B (en) | Anthelmintic combination | |
| CN103405388B (en) | Wettable moxidectin solid dispersing powder as well as preparation method and application thereof | |
| CN101854926A (en) | Endoparasiticidal topical compositions | |
| CN103893184B (en) | Comprise the local medicine composition of activating agent | |
| CN103417486B (en) | A kind of wettable ivermectin solid dispersion powder and its production and use | |
| CN103340885B (en) | Wettable albendazole ivermectin powder | |
| TW200800293A (en) | Benzimidazole non-aqueous compositions | |
| CN103536536B (en) | Wettability solid dispersing powder of florfenicol composition and preparation method thereof | |
| US20160303157A1 (en) | Method for preparing an anthelmintic composition, anthelmintic composition, veterinary treatment method and anthelmintic treatment method | |
| AU2011268899C1 (en) | Injectable formulation of a macrocyclic lactone and levamisole | |
| CN102949340A (en) | Sarah rhzomorph nano emulsion medicine composition and preparation method thereof | |
| JP2013542737A (en) | Methods for inhibiting insect invasion | |
| CN110179756A (en) | A kind of tilmicosin micro-capsule preparation and preparation method thereof | |
| CN103536604B (en) | A kind of wettable sulfamethoxazole trimethoprim powder and preparation method thereof | |
| CN108210452B (en) | Veterinary cyadox nano suspension and preparation method thereof | |
| Krugner-Higby et al. | Liposome-encapsulated oxymorphone hydrochloride provides prolonged relief of postsurgical visceral pain in rats | |
| CN103417484B (en) | Wettable doramectin solid dispersion powder and preparation method and application thereof | |
| Marchenko et al. | Efficacy of novel formulations of ivermectin and albendazole in parasitic infections of sheep in the Altai mountains of Russia | |
| CN103417485B (en) | A kind of wettable eprinomectin solid dispersion powder and its production and use | |
| CN103393600B (en) | A kind of wettable milbemycin oxime solid divides loose powder and its production and use | |
| WO2009043226A1 (en) | A stable liquid composition comprising taxan derivatives and its preparation method. | |
| WO2001064222A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
| AU2001235489A1 (en) | Veterinary compositions for the treatment of parasitic diseases | |
| CN103393706B (en) | A kind of wettable ivermectin albendazole oxide powder | |
| WO2015053636A1 (en) | Veterinary formulations and methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee after: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL CO.,LTD. Patentee after: SHANGHAI SIMENON BIOTECHNOLOGY Co.,Ltd. Address before: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee before: CHENGDU QIANKUN VETERINARY PHARMACEUTICAL Co.,Ltd. Patentee before: SHANGHAI SIMENON BIOTECHNOLOGY Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150408 |